Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen
ProDLBCL
1 other identifier
observational
1,927
2 countries
39
Brief Summary
This study is a retrospective analysis of an homogeneous population of patients with aggressive B-cell lymphoma and treated upfront with R-CHOP or R-CHOP like regimens to reassess the prognostic factors and hopefully to identify more accurate prognostic subgroups with a clinical and therapeutical relevance.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2009
39 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2011
CompletedFirst Submitted
Initial submission to the registry
October 12, 2011
CompletedFirst Posted
Study publicly available on registry
November 23, 2011
CompletedNovember 23, 2011
November 1, 2011
2 years
October 12, 2011
November 22, 2011
Conditions
Keywords
Study Arms (1)
Cases of aggressive B-cell lymphoma
Cases of aggressive B-cell lymphoma diagnosed between 2001 to 2007 in Italy
Eligibility Criteria
Cases of aggressive B-cell lymphoma diagnosed between 2001 to 2007 in Italy
You may qualify if:
- Histologically confirmed newly diagnosed aggressive B-cell lymphoma according to the current World Health Organisation Classification, from 2001 to 2007.
- Any stage of disease.
- Treatment with R-CHOP or R-CHOP like regimens (+/- transplant).
- Age at least 18 years.
- Availability of tissue biopsy at diagnosis for a possible centralized revision.
- Availability of data on clinical involvement, laboratory, treatment and follow up.
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (39)
Hemocentro-Unicamp
Campinas, Brazil
Centro Medico
Santa Isabel, Brazil
Centro Paulista de Oncologia
São Paulo, Brazil
Santa Casa Medical School
São Paulo, Brazil
Clinica Ematologica Policlinico Carreggi
Florence, Firenze, 50134, Italy
Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori
Milan, Milano, Italy
A.O.SS. Biagio, Antonio e Cesare Arrigo
Alessandria, Italy
Centro di riferimento Oncologico Oncologia Medica A
Aviano (Pordenone), Italy
USC Ematologia e Trapianto di Midollo Osseo Ospedali Riuniti di Bergamo
Bergamo, Italy
Presidio Ospedaliero A.Perrino - Divisione di Ematologia
Brindisi, Italy
U.O. di Oncologia Ospedale di Circolo di Busto Arsizio
Busto Arsizio, Italy
Ospedale Civile
Camposanpiero (PD), Italy
A.O.Pugliese Ciaccio Diviisone di Ematologia
Catanzaro, Italy
Presidio Ospedaliero Annunziata U.O.C. di Ematologia
Cosenza, Italy
Ematologia 1 Ospedale S. Martino
Genova, 16132, Italy
Oncologia Medica B e C IST Genova
Genova, Italy
Ospedale Felettino
La Spezia, Italy
Ospedale Madonna delle grazie U.O. Ematologia
Matera, Italy
A O Papardo
Messina, Italy
Azienda Ospedaliero Universitaria Policlinico Gaetano Martino
Messina, Italy
Oncologia Medica 3 Istituto Nazionale dei Tumori di Milano
Milan, Italy
Osp. San Carlo Borromeo Divisione di Oncologia Medica
Milan, Italy
Ospedale Maggiore IRCCS-Dipartimento di Ematologia
Milan, Italy
Centro Oncologico Modenese
Modena, Italy
A.O. Maggiore della Carità S.C.D.U. Ematologia
Novara, Italy
A.O. di Padova Divisione di Oncologia Medica
Padua, Italy
Casa di cura La Maddalena Unita' di Ematologia
Palermo, Italy
Div. di Ematologia e TMO AOU Policlinico Giaccone di Palermo
Palermo, Italy
A O Universitaria di Parma
Parma, Italy
Ospedale Civile G.da Saliceto - UOA Ematologia
Piacenza, Italy
Azienda Ospedaliero Universitaria Pisana U.O. Ematologia
Pisa, Italy
AO Bianchi Melacrino Morelli UO Ematologia
Reggio Calabria, Italy
AO Arcispedale S.Maria Nuova Ematologia
Reggio Emilia, Italy
Ospedale Oncologico regionale CROB
Rionero in Vulture (PZ), Italy
Dipartimento di biotecnologie cellulari ed ematologia Ospedale Umberto I - La Sapienza
Roma, Italy
Policlinico A. Gemelli Università Cattolica del Sacro Cuore
Roma, Italy
Clinica Humanitas
Rozzano (MI), Italy
A.O.San Giovanni Battista
Torino, Italy
U.O. Oncologia Azienda ULSS7 P.O. di Vittorio Veneto
Vittorio Veneto, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Massimo Federico, MD
Oncologia II Azienda Ospedaliera Universitaria di Modena
- PRINCIPAL INVESTIGATOR
Stefano Luminari, MD
Oncologia II Azienda Ospedaliera Universitaria di Modena
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 12, 2011
First Posted
November 23, 2011
Study Start
May 1, 2009
Primary Completion
May 1, 2011
Study Completion
May 1, 2011
Last Updated
November 23, 2011
Record last verified: 2011-11